Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: a case-control study.
Multidrug resistant
Risk factors
Sudan
Tuberculosis
Journal
Epidemiology and health
ISSN: 2092-7193
Titre abrégé: Epidemiol Health
Pays: Korea (South)
ID NLM: 101519472
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
04
2019
accepted:
20
04
2019
pubmed:
24
4
2019
medline:
30
5
2019
entrez:
24
4
2019
Statut:
ppublish
Résumé
The emergence of multidrug-resistant tuberculosis (MDR-TB) is a major challenge for the global control of tuberculosis (TB). The aim of this study was to determine the risk factors associated with MDR-TB in Sudan. This case-control study was conducted from May 2017 to February 2019. Patients newly diagnosed with MDR-TB were selected as cases, and controls were selected from TB patients who responded to first-line anti-TB drugs. A questionnaire was designed and used to collect data from study participants. Logistic regression was used to evaluate associations between risk factors and MDR-TB infection. The best multivariate model was selected based on the likelihood ratio test. A total of 430 cases and 860 controls were selected for this study. A history of previous TB treatment (adjusted odds ratio [aOR], 54.85; 95% confidence interval [CI], 30.48 to 98.69) was strongly associated with MDR-TB infection. We identified interruption of TB treatment (aOR, 7.62; 95% CI, 3.16 to 18.34), contact with MDR-TB patients (aOR, 5.40; 95% CI, 2.69 to 10.74), lower body weight (aOR, 0.89; 95% CI, 0.87 to 0.91), and water pipe smoking (aOR, 3.23; 95% CI, 1.73 to 6.04) as factors associated with MDR-TB infection. Previous TB treatment and interruption of TB treatment were found to be the main predictors of MDR-TB. Additionally, this study found that contact with MDR-TB patients and water pipe smoking were associated with MDR-TB infection in Sudan. More efforts are required to decrease the rate of treatment interruption, to strengthen patients' adherence to treatment, and to reduce contact with MDR-TB patients.
Identifiants
pubmed: 31010280
pii: epih.e2019014
doi: 10.4178/epih.e2019014
pmc: PMC6545493
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2019014Références
Int J STD AIDS. 2003 Aug;14(8):514-8
pubmed: 12935379
Microb Drug Resist. 2005 Spring;11(1):62-7
pubmed: 15770097
Thorax. 2006 Feb;61(2):158-63
pubmed: 16254056
S Afr Med J. 2007 Nov;97(11 Pt 3):1120-8
pubmed: 18250922
Int J Tuberc Lung Dis. 2009 Jan;13(1):68-73
pubmed: 19105881
PLoS One. 2010 Dec 29;5(12):e15735
pubmed: 21209951
Tuberculosis (Edinb). 2011 Mar;91(2):173-8
pubmed: 21251881
Int J Infect Dis. 2013 Dec;17(12):e1116-20
pubmed: 23916547
PLoS One. 2013 Aug 14;8(8):e67338
pubmed: 23967048
BMC Public Health. 2013 Aug 28;13:782
pubmed: 23981845
PLoS One. 2014 Aug 19;9(8):e105214
pubmed: 25136966
Emerg Infect Dis. 2015 Mar;21(3):409-16
pubmed: 25693485
Afr Health Sci. 2015 Jun;15(2):368-77
pubmed: 26124781
BMJ Open. 2015 Sep 08;5(9):e008273
pubmed: 26351185
BMC Public Health. 2015 Oct 06;15:1027
pubmed: 26444417
Int J Mycobacteriol. 2015 Mar;4(1):44-7
pubmed: 26655197
BMC Public Health. 2016 Jan 16;16:42
pubmed: 26775263
BMC Proc. 2015 Dec 18;9(Suppl 10):S4
pubmed: 28281702
Infect Drug Resist. 2017 Mar 13;10:91-96
pubmed: 28331350
Rev Saude Publica. 2017 Apr 27;51(0):41
pubmed: 28489185
J Trop Med. 2017;2017:9241238
pubmed: 28808447
PLoS One. 2017 Sep 25;12(9):e0185105
pubmed: 28945771
Health Policy Plan. 2017 Oct 1;32(suppl_2):i43-i50
pubmed: 29028228
BMC Public Health. 2018 Apr 2;18(1):422
pubmed: 29606112
Confl Health. 2018 May 16;12:18
pubmed: 29785203
Infect Drug Resist. 2018 Jun 12;11:873-887
pubmed: 29928135
BMC Public Health. 2018 Sep 12;18(1):1114
pubmed: 30208864
N Engl J Med. 1993 Feb 25;328(8):527-32
pubmed: 8426619